Why Dipyridamole is NOT Used in Angina

What Dipyridamole Does

1. Inhibiting phosphodiesterase - raises intracellular cAMP levels
2. Blocking adenosine reuptake - increases extracellular adenosine, which acts on A2A receptors to dilate coronary resistance arterioles

The Core Reason: Coronary Steal Phenomenon

Normal physiology in ischemic heart disease

• In a patient with atherosclerotic coronary stenosis, the arterioles downstream of the blockage are already maximally dilated due to local autoregulatory mechanisms (hypoxia, adenosine, etc.) - they are working at their maximum capacity just to maintain resting perfusion.
• The arterioles in normal, well-perfused regions are in a resting, partially constricted state - they still have the capacity to dilate further.

What happens when dipyridamole is given

• Dipyridamole causes powerful dilation of all coronary arterioles.
• The arterioles in normal regions dilate widely (they had the capacity to do so).
• The arterioles in the ischemic region cannot dilate any further (already maximally dilated).
• This creates a large pressure gradient that diverts ("steals") blood flow away from the ischemic region into the now-dilated normal regions.
• The ischemic myocardium receives even less blood - ischemia worsens.

Contrast: Why Nitrates DO Work in Angina

• Nitrates act primarily on large epicardial conductance arteries and venous capacitance vessels - not on small resistance arterioles.
• They dilate the large coronary vessels upstream of a stenosis, improving flow distal to the blockage.
• They reduce preload (venodilation) and afterload, lowering myocardial O2 demand.
• They increase collateral flow to ischemic regions.

How the Coronary Steal Mechanism is Exploited

• Dipyridamole stress test: Given IV before myocardial perfusion imaging (e.g., thallium/technetium scan). It provokes the steal phenomenon, unmasking ischemia in territories supplied by stenosed vessels. This is used as a pharmacological stress test in patients who cannot exercise. - Goodman & Gilman's

Summary Table

Additional Adverse Effects

• Headache and dizziness (vasodilatory)
• Orthostatic hypotension (especially IV)
• These further limit its utility in cardiac patients - Lippincott Illustrated Reviews: Pharmacology

Statins + Fibrates for Hyperlipidemia

1. Why Combine Them? (Rationale)

Indications for Combination

• Mixed hyperlipidemia (elevated LDL-C + elevated TG + low HDL-C) - the most common indication
• Type IIb hyperlipoproteinemia (elevated VLDL + LDL)
• Patients with metabolic syndrome or Type 2 diabetes who fail monotherapy
• Patients at high CV risk who need broader lipid panel control - Katzung's Basic and Clinical Pharmacology, 16th Ed.

2. Mechanism of Fibrates (in Detail)

1. ↑ Lipoprotein lipase (LPL) activity - by increasing apoC-II (LPL activator) and decreasing apoC-III (LPL inhibitor) - hydrolyses TG in chylomicrons and VLDL
2. ↑ Hepatic expression of apoA-I and apoA-II - raises HDL
3. ↑ Fatty acid β-oxidation - reduces hepatic VLDL synthesis
4. HDL is also raised because surface coat material from VLDL particles is recycled into HDL - Textbook of Family Medicine, 9th Ed.

Important caveat - the "B-effect"

3. Clinical Evidence

ACCORD Lipid Trial

• Added fenofibrate to simvastatin in patients with Type 2 diabetes
• Overall result: no significant reduction in primary CV outcomes compared to statin alone
• However, post-hoc subgroup analysis found a 31% reduction in CV events in patients with the combination of high TG (≥204 mg/dL) + low HDL-C (≤34 mg/dL)
• This suggests the combination benefits a specific phenotype: atherogenic dyslipidemia - Comprehensive Clinical Nephrology, 7th Ed.; Textbook of Family Medicine

VA-HIT Trial (Gemfibrozil monotherapy)

• Men with CAD and low HDL-C treated with gemfibrozil: 22% reduction in all-cause mortality and nonfatal MI, 31% reduction in stroke risk
• Underscores the value of TG-lowering/HDL-raising in the right patient population - Textbook of Family Medicine

FIELD and Helsinki Heart Studies

• Post-hoc subgroup analyses: fenofibrate/fibrate reduced CV events by 27-31% in patients with high TG + low HDL - Textbook of Family Medicine

4. The Critical Safety Concern: Myopathy / Rhabdomyolysis

Mechanism of the Drug Interaction

• Statin plasma levels rise substantially
• Myopathy and rhabdomyolysis risk increases dramatically - Textbook of Family Medicine

Risk Quantification (Goldman-Cecil Medicine)

Which fibrate to use?

• It does NOT significantly inhibit glucuronidation of statins
• Better pharmacokinetic safety profile
• Goldman-Cecil: gemfibrozil "should be avoided" in statin-treated patients
• Katzung's: "Fenofibrate is the fibrate of choice for use in combination with a statin"

5. Additional Risks of the Combination

6. Practical Clinical Guidelines

1. Prefer fenofibrate over gemfibrozil when combining with a statin
2. Use the lowest effective statin dose when combined
3. Avoid the combination in advanced CKD (high rhabdomyolysis risk)
4. Monitor CK at baseline and if patient develops muscle symptoms (pain, weakness, dark urine)
5. Monitor LFTs at 6-12 weeks and biannually
6. Adjust warfarin if the patient is on anticoagulation
7. Consider omega-3 fatty acids (icosapent ethyl/EPA) as an alternative to adding a fibrate in statin-treated patients - lower myopathy risk, and the REDUCE-IT trial showed significant CV benefit with high-dose EPA + statin - Washington Manual of Medical Therapeutics; Goldman-Cecil Medicine

7. Alternative to Statin + Fibrate: Statin + Omega-3

Summary

Why Apixaban is Used in Atrial Fibrillation

1. The Problem: Why AF Causes Stroke

• Loss of effective atrial contraction
• Blood stasis, particularly in the left atrial appendage (LAA) - a blind-ended pouch off the left atrium with low flow
• Stasis activates the coagulation cascade → thrombus formation in the LAA
• The thrombus can embolize to the cerebral circulation → ischemic stroke

• Nonrheumatic AF is the most common cause of cardioembolic stroke overall
• Patients with AF have an average annual stroke risk of ~5% - roughly 5x higher than the general population
• AF accounts for one-sixth of all strokes - Symptom to Diagnosis, 4th Ed.
• Stroke risk in untreated AF is substantially higher in rheumatic AF

2. Why Anticoagulation (Not Antiplatelet Therapy) is Needed

• Antiplatelet drugs (aspirin, clopidogrel) are insufficient - they target platelet activation but not the fibrin-rich thrombus of AF
• The ACTIVE-W trial showed aspirin + clopidogrel was inferior to warfarin for AF stroke prevention
• The AVERROES trial showed apixaban significantly reduced stroke risk vs aspirin with no significant difference in major bleeding in patients unsuitable for VKAs - Fuster and Hurst's The Heart, 15th Ed.
• Full anticoagulation is required to suppress fibrin clot formation in the atrium

3. What Apixaban Is and How It Works

Mechanism of Action

Coagulation cascade:

Intrinsic/Extrinsic pathway
         ↓
     Factor X
         ↓  ← APIXABAN BLOCKS HERE (directly inhibits Factor Xa)
     Factor Xa
         ↓
  Prothrombin (II) → Thrombin (IIa)
         ↓
  Fibrinogen → Fibrin (clot)

• Apixaban binds directly and reversibly to the active site of Factor Xa - no need for a cofactor (unlike heparin, which requires antithrombin)
• Inhibiting Factor Xa prevents the conversion of prothrombin to thrombin
• Without thrombin, fibrinogen cannot be converted to fibrin - no clot forms
• This prevents thrombus formation in the fibrillating atrium and LAA - Goldman-Cecil Medicine

Pharmacokinetic Profile (Goldman-Cecil Medicine)

4. Why Apixaban is Preferred Over Warfarin

5. Key Clinical Trial: ARISTOTLE

6. When to Use Apixaban - CHA₂DS₂-VASc Risk Stratification

• Score 0: Very low stroke risk - no anticoagulation
• Score 1: Anticoagulation at physician/patient discretion
• Score ≥ 2: Anticoagulation recommended - apixaban (or other DOAC) is first choice

7. Dosing and Dose Reduction

• Standard dose: Apixaban 5 mg twice daily (oral)
• Reduced dose: 2.5 mg twice daily - if patient meets ≥2 of the following criteria:
  • Age ≥ 80 years
  • Body weight ≤ 60 kg
  • Serum creatinine ≥ 1.5 mg/dL

8. Valvular vs Non-valvular AF

• For AF with mechanical prosthetic valves or rheumatic mitral stenosis - warfarin remains the anticoagulant of choice (DOACs have not been shown to be effective and may be harmful in this setting) - Goldman-Cecil Medicine

9. Reversal if Bleeding Occurs

Summary

1. AF causes left atrial appendage thrombus and stroke through blood stasis
2. Prevention requires anticoagulation (not antiplatelet therapy)
3. Apixaban directly inhibits Factor Xa, blocking thrombin and fibrin clot formation
4. The ARISTOTLE trial proved it is superior to warfarin in both preventing stroke AND causing less bleeding
5. It offers practical advantages over warfarin: fixed dosing, no INR monitoring, fewer drug/food interactions
6. Its low renal clearance makes it more versatile than dabigatran
7. A specific reversal agent (andexanet alfa) is available for emergencies